NanoPalm develops advanced Lipid Nanoparticle (LNP) manufacturing processes for in-vivo gene therapies. Their technology creates stable, self-targeting LNPs designed to deliver genetic material to specific organs and cells, aiming to improve the efficacy and safety of gene therapies for genetic diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current in-vivo gene therapies face challenges in delivering genetic material to specific organs and cells effectively and safely, often resulting in off-target effects and limited therapeutic efficacy. Traditional Lipid Nanoparticle (LNP)-based therapies can suffer from instability and lack the precision needed for targeted delivery, leading to potential toxicity and suboptimal patient outcomes. The high cost and lengthy timelines associated with drug discovery and clinical trials further impede the development of affordable gene therapies.
Solution
NanoPalm is developing advanced LNP manufacturing processes that leverage a proprietary AI platform, EnsaliX, to design stable, self-targeting LNPs for in-vivo gene therapies. These LNPs are engineered to deliver genetic material with enhanced precision, improving efficacy and reducing off-target effects. NanoPalm's technology aims to accelerate and reduce the cost of R&D by predicting optimal nanomedicine formulations with high confidence of clinical success. By controlling the architecture, shape, size, and surface chemistry of LNPs, NanoPalm enables the creation of custom-designed nanoformulations that can target specific organs and cells within the human body.
Target Audience
NanoPalm's primary customers are biopharmaceutical companies and research institutions focused on developing gene therapies for genetic diseases, as well as investors interested in supporting innovative nanomedicine technologies.
Features
- AI-driven LNP design using the proprietary EnsaliX platform for optimized safety, stability, and selectivity
- Custom-designed nanoformulations for targeted delivery to specific organs and cells
- Cochleate BioRobot: Proprietary lipid-based nanoparticles for oral delivery of RNA and DNA
- DLC BioRobot: Discotic Liquid Crystal (DLC) BioRobot for nucleic acid delivery directly into 3D matrix of disease-on-a-dish
- Cell-specific BioRobots for targeted therapy delivery to specific cells, such as rod cells
- Nanoconfinement technology for shape control over lipid assemblies
- Nanolithographic process for fabricating stable LNPs with controlled architecture, shape, size, and surface chemistry